CATALAYER NEWS
Shionogi-Backed Biotech Apnimed Raises $192 Million in US IPO
Source: Bloomberg Markets · 2026-07-31
Apnimed Inc., a late-stage drug developer focused on sleep apnea, raised $192 million in an upsized US initial public offering, priced at the top of a marketed range.
MORE FROM BLOOMBERG MARKETS
North Korea’s Economy Expands on Russia Arms Deals, China Trade
2026-07-31
Philippines to Revamp Bond Pricing Ahead of JPM Index Inclusion
2026-07-31
Nikkei Weight Cut Shadow Looms Over Advantest After 18% Rally
2026-07-31
Japan Preempts Market With Yen Intervention
2026-07-31
Iron Ore Climbs as Traders Weigh Supply Risks From BHP Strike
2026-07-31
RELATED ON CATALAYER
RELATED MARKETS
Prediction Markets